ENHERTU Mechanism of Action
This promotional website is
intended for UK healthcare professionals only
This promotional website is intended for UK healthcare professionals only
- Adverse event reporting
- UK Prescribing Information
- Contact us
ENHERTU (trastuzumab deruxtecan) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens1
ENHERTU as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy1
Enhertu has a Conditional Marketing Authorisation
Prescribing Information can be accessed from the link at the top right of this website
Video Resources
Video thumbnail for Enhertu mode of action
Optimising Second Line Treatment for HER2+ Metastatic Breast Cancer: Efficacy and Safety Data for Enhertu
Sequencing in HER2+ Metastatic Breast Cancer
Expert Insights: Exploratory Analysis of Trastuzumab Deruxtecan-Responders in the Destiny-Breast Trials
Downloadable Resources
ILD Awareness Letter for GPs
A template letter intended for oncology HCPs to send to a patient’s GP to inform
the GP that their patient has been initiated on Enhertu▼ (trasuzumab deruxtecan) for metastatic breast cancer and alert them to the risk of ILD, its symptoms and the need for prompt referral if suspected.
ILD UK BCG Guidance flyer
A flyer providing details on the UK Breast Cancer Group (BCG) guidance for the
monitoring and management of Enhertu-related ILD (interstitial lung disease)
Anti-emetic guidelines flyer
A flyer providing details on the recommended guidelines for prophylactic
anti-emetic medication prior to ENHERTU use
RISK MINIMISATION MATERIALS FOR ENHERTU
To access ENHERTU risk minimisation materials (RMM), please visit the electronic medicines compendium (emc) where you can find the following:
HCP guide for prevention of product confusion medication errors
This material serves to minimise the important potential risk of medication error in addition to the SmPC.
HCP guide: important safety information on ILD/pneumonitis with treatment of ENHERTU
This guide is an important tool to ensure the early recognition and diagnosis of interstitial lung disease (ILD)/pneumonitis, to allow prompt and appropriate treatment and minimise serious outcomes.
Patient Card: ENHERTU
The Patient Card is intended to help patients identify symptoms of lung problems that they may experience with ENHERTU treatment.
Abbreviations
ILD, interstitial lung disease; RMM, risk minimisation materials.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App store. Adverse events should also be reported to Daiichi Sankyo UK Pharmacovigilance on 0800 028 5122 or by email to pharmacovigilance@daiichi-sankyo.co.uk. As ENHERTU is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.
Reference
- ENHERTU (trastuzumab deruxtecan). Summary of Product Characteristics.
UK/ADC/01/25/0011 | April 2025
